NCT04652349View on ClinicalTrials.gov

Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

December 17, 2020

Study Completion Date

January 14, 2021

Conditions
Primary Hypercholesterolemia
Interventions
DRUG

HGP1910

Take it once daily for 8 weeks orally.

DRUG

HCP1903

Take it once daily for 8 weeks orally.

DRUG

HGP1909

Take it once daily for 8 weeks orally.

DRUG

HGP1911

Take it once daily for 8 weeks orally.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04652349 - Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia | Biotech Hunter | Biotech Hunter